Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 1, 1999, Pages 67-69

  Pirich, Laura M ^a   Chou, Pauline ^a   Walterhouse, David O ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Renal medullary carcinoma; Sickle cell trait

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; TOPOTECAN; VINBLASTINE;

ARTICLE; CANCER SURVIVAL; CASE REPORT; CHEMOTHERAPY; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; LABORATORY TEST; MALE; MEDULLARY CARCINOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SICKLE CELL TRAIT; TREATMENT OUTCOME;

EID: 0033063652     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199901000-00015     Document Type: Article

References (6)

1. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
2. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etopo-side (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group phase I/II study. J Pediatr Hematol Oncol 1994;17:265-9.
3. Tubergen DG, Stewart CR, Pratt CB, et al. Phase I trial and pharmacodynamics study of topotecan using a five day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1996;18:352-61.
4. Davidson AJ, Choyke PL, Hartman DS, et al. Renal medullary carcinoma associated with sickle cell trait: radiographic findings. Radiology 1995;195:83-5.
5. Berman LB. Sickle cell nephropathy [letter]. JAMA 1974;228:1279.
6. Avery RA, Harris JE, Davis CJ, et al. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996;78:128-32.